Epigenetics

Epigenetics is the control of gene expression without altering the DNA sequence, including DNA methylation, genomic imprinting, maternal effects, gene silencing, nucleolus dominant, dormant transposon activation, and RNA editing. In contrast to classical genetics, which focuses on the effects of gene sequences on biological functions, epigenetics focuses on the mechanisms by which these "epigenetic phenomena" are established and maintained.

Cat. No.	Product name
BP13996	Darovasertib
BP13996	LXS196 is a potent, selective and orally active protein kinase C (PKC) inhibitor(IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively).
BP13995	LT052
BP13995	LT052 shows nanomolar BRD4 BD1 potency and 138-fold selectivity over BRD4 BD2. LT052 has inhibitory activities against BRPF1b (IC50=567.5 nM). LT052 has anti-inflammatory activity. LT052 is a highly selective BET BD1 inhibitor. LT052 displays inhibitory activity against BRD4 (BD1), BRD3 (BD1) and BRDT (BD1) with IC50s of 87.7, 246.3, and 357.1 nM, respectively.
BP13994	Pulrodemstat benzenesulfonate
BP13994	LSD1-IN-7 benzenesulfonate is a potent and orally active inhibitor of lysine specific demethylase-1 (LSD1) with anticancer activity.
BP13993	LSD1-IN-6
BP13993	LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1. LSD1-IN-6 is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 123 nM.
BP13992	LSD1-IN-5
BP13992	LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1. LSD1-IN-5 is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 121 nM.
BP13991	LP99
BP13991	LP99 is an epigenetic probe. LP99 disrupts the binding of BRD7 and BRD9 to chromatin in cells. LP99 is an effective and selective inhibitor of the BRD7 and BRD9 bromodomains (Kd: 99 nM against BRD9).
BP13990	Lomeguatrib
BP13990	Lomeguatrib, a modified guanine base, inhibits the activity of DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (MGMT).
BP13989	LMK-235
BP13989	LMK-235 is a potent HDAC inhibitor, and is used in cancer research.
BP13988	LLY-507
BP13988	LLY-507 is an effective, cell-active, and specific inhibitor of protein-lysine Methyltransferase SMYD2.
BP13987	Ligupurpuroside C
BP13987	Ligupurpuroside C can significantly inhibit lipid accumulation in HepG2 cell at the concentration of 50 μMol/L.
BP13986	Ligupurpuroside A
BP13986	Ligupurpuroside A has antioxidant,and hypolipidemic effects, it can significantly inhibit lipid accumulation in HepG2 cell at the concentration of 50 μMol/L.
BP13985	Levetiracetam
BP13985	Levetiracetam is a relatively unique anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Levetiracetam has been linked to rare instances of serum aminotransferase and alkaline phosphatase elevations during treatment and to rare cases of clinically apparent drug induced liver disease.
BP13984	Leucosceptoside A
BP13984	Leucosceptoside A shows inhibitory activity against PKCalpha with the IC50 value of 19.0 microM; it also exhibits strong inhibitory capacity against α-glucosidase. Leucosceptoside A has antihypertensive effect, it shows angiotensin converting enzyme (ACE) inhibitory effect in a dose-dependent manner of which IC(50) value of 423+/-18.8 microg/ml.
BP13983	Lasiodin
BP13983	Lasiodin has anti-oxidative, and antineoplastic activities, it also shows antibacterial activity, esp. against Sarcina lutea.
BP13982	L-2-Hydroxyglutaric acid disodium
BP13982	L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity(Km and Ki of 2.52 mM and 11.13 mM, respectively).
BP13981	L002
BP13981	L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation. L002 has the potential for hypertension‐induced cardiac hypertrophy and fibrogenesis treatment. L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM.
BP13980	Kuguaglycoside C
BP13980	Kuguaglycoside C induces caspase-independent cell death, and is involved, at least in part, in the mechanism underlying cell necroptosis.
BP13979	Kudinoside D
BP13979	Kudinoside D exerts anti-adipogenic effects through modulation of adipogenic transcription factors via AMPK signaling pathway.
BP13978	Gardenia yellow
BP13978	Kuchinashi yellow has anti atherosclerosis and hypolipidemic effects.
BP13977	KI696 isomer
BP13977	KI696 is a high affinity probe that disrupts the Keap1/NRF2 interaction. KI696 isomer is the less active isomer of KI696.